|
1
|
Doroshow DB, Bhalla S, Beasley MB, Sholl
LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS and Hirsch FR:
PD-L1 as a biomarker of response to immune-checkpoint inhibitors.
Nat Rev Clin Oncol. 18:345–362. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Blank C, Gajewski TF and Mackensen A:
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T
cells as a mechanism of immune evasion: Implications for tumor
immunotherapy. Cancer Immunol Immunother. 54:307–314. 2005.
View Article : Google Scholar
|
|
3
|
Cha JH, Chan LC, Li CW, Hsu JL and Hung
MC: Mechanisms controlling PD-L1 expression in cancer. Mol Cell.
76:359–370. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Butte MJ, Keir ME, Phamduy TB, Sharpe AH
and Freeman GJ: Programmed death-1 ligand 1 interacts specifically
with the B7-1 costimulatory molecule to inhibit T cell responses.
Immunity. 27:111–122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Akinleye A and Rasool Z: Immune checkpoint
inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol.
12:922019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yin L, Duan JJ, Bian XW and Yu SC:
Triple-negative breast cancer molecular subtyping and treatment
progress. Breast Cancer Res. 22:612020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Won KA and Spruck C: Triple-negative
breast cancer therapy: Current and future perspectives (Review).
Int J Oncol. 57:1245–1261. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Elmakaty I, Abdo R, Elsabagh A, Elsayed A
and Malki MI: Comparative efficacy and safety of PD-1/PD-L1
inhibitors in triple negative breast cancer: A systematic review
and network meta-analysis of randomized controlled trials. Cancer
Cell Int. 23:902023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ahn SG, Kim SK, Shepherd JH, Cha YJ, Bae
SJ, Kim C, Jeong J and Perou CM: Clinical and genomic assessment of
PD-L1 SP142 expression in triple-negative breast cancer. Breast
Cancer Res Treat. 188:165–178. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu Y, Jin X, Zhu X, Xu Y, Si W and Zhao J:
PD-1/PD-L1 immune checkpoint inhibitors in metastatic
triple-negative breast cancer: A systematic review and
meta-analysis. Front Immunol. 14:12066892023. View Article : Google Scholar :
|
|
11
|
Cortes J, Rugo HS, Cescon DW, Im SA, Yusof
MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, et
al: Pembrolizumab plus chemotherapy in advanced triple-negative
breast cancer. N Engl J Med. 387:217–226. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schmid P, Rugo HS, Adams S, Schneeweiss A,
Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, et
al: Atezolizumab plus nab-paclitaxel as first-line treatment for
unresectable, locally advanced or metastatic triple-negative breast
cancer (IMpassion130): Updated efficacy results from a randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet Oncol.
21:44–59. 2020. View Article : Google Scholar
|
|
13
|
Loibl S, Schneeweiss A, Huober J, Braun M,
Rey J, Blohmer JU, Furlanetto J, Zahm DM, Hanusch C, Thomalla J, et
al: Neoadjuvant durvalumab improves survival in early
triple-negative breast cancer independent of pathological complete
response. Ann Oncol. 33:1149–1158. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ren D, Hua Y, Yu B, Ye X, He Z, Li C, Wang
J, Mo Y, Wei X, Chen Y, et al: Predictive biomarkers and mechanisms
underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.
Mol Cancer. 19:192020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brummel K, Eerkens AL, de Bruyn M and
Nijman HW: Tumour-infiltrating lymphocytes: From prognosis to
treatment selection. Br J Cancer. 128:451–458. 2023. View Article : Google Scholar :
|
|
16
|
Angelico G, Broggi G, Tinnirello G, Puzzo
L, Vecchio GM, Salvatorelli L, Memeo L, Santoro A, Farina J, Mulé
A, et al: Tumor infiltrating lymphocytes (TILS) and PD-L1
expression in breast cancer: A review of current evidence and
prognostic implications from pathologist's perspective. Cancers
(Basel). 15:44792023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Salgado R, Denkert C, Demaria S, Sirtaine
N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL,
Penault-Llorca F, et al: The evaluation of tumor-infiltrating
lymphocytes (TILs) in breast cancer: Recommendations by an
international TILs working group 2014. Ann Oncol. 26:259–271. 2015.
View Article : Google Scholar
|
|
18
|
Ahmed H, Mahmud AR, Siddiquee MF, Shahriar
A, Biswas P, Shimul MEK, Ahmed SZ, Ema TI, Rahman N, Khan MA, et
al: Role of T cells in cancer immunotherapy: Opportunities and
challenges. Cancer Pathog Ther. 1:116–126. 2023. View Article : Google Scholar
|
|
19
|
June CH: Adoptive T cell therapy for
cancer in the clinic. J Clin Invest. 117:1466–1476. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Porta FM, Sajjadi E, Venetis K,
Frascarelli C, Cursano G, Guerini-Rocco E, Fusco N and Ivanova M:
Immune biomarkers in triple-negative breast cancer: Improving the
predictivity of current testing methods. J Pers Med. 13:11762023.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Curtis C, Shah SP, Chin SF, Turashvili G,
Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et
al: The genomic and transcriptomic architecture of 2,000 breast
tumours reveals novel subgroups. Nature. 486:346–352. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pereira B, Chin SF, Rueda OM, Vollan HK,
Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut S, et
al: The somatic mutation profiles of 2,433 breast cancers refines
their genomic and transcriptomic landscapes. Nat Commun.
7:114792016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
25
|
Shan D, Chen L, Njardarson JT, Gaul C, Ma
X, Danishefsky SJ and Huang XY: Synthetic analogues of migrastatin
that inhibit mammary tumor metastasis in mice. Proc Natl Acad Sci
USA. 102:3772–3776. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Teng MW, Ngiow SF, Ribas A and Smyth MJ:
Classifying cancers based on T-cell infiltration and PD-L1. Cancer
Res. 75:2139–2145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Filho PN, Albuquerque C, Capella MP and
Debiasi M: Immune checkpoint inhibitors in breast cancer: A
narrative review. Oncol Ther. 11:171–183. 2023. View Article : Google Scholar
|
|
28
|
Herbst RS, Soria JC, Kowanetz M, Fine GD,
Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger
SN, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Taube JM, Anders RA, Young GD, Xu H,
Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL
and Chen L: Colocalization of inflammatory response with B7-h1
expression in human melanocytic lesions supports an adaptive
resistance mechanism of immune escape. Sci Transl Med.
4:127ra1372012. View Article : Google Scholar
|
|
30
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Badve SS, Penault-Llorca F, Reis-Filho JS,
Deurloo R, Siziopikou KP, D'Arrigo C and Viale G: Determining PD-L1
status in patients with triple-negative breast cancer: Lessons
learned from IMpassion130. J Natl Cancer Inst. 114:664–675. 2022.
View Article : Google Scholar :
|
|
32
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schmid P, Chui SY and Emens LA:
Atezolizumab and nab-paclitaxel in advanced triple-negative breast
cancer. Reply. N Engl J Med. 380:987–988. 2019.PubMed/NCBI
|
|
34
|
Schmid P, Cortes J, Pusztai L, McArthur H,
Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, et al:
Pembrolizumab for early triple-negative breast cancer. N Engl J
Med. 382:810–821. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee
JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers
S, Salman P, et al: Nivolumab plus ipilimumab in lung cancer with a
high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yuan Y, Adam A, Zhao C and Chen H: Recent
advancements in the mechanisms underlying resistance to PD-1/PD-L1
blockade immunotherapy. Cancers (Basel). 13:6632021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang L, Hu Q and Huang T: Breast cancer
treatment strategies targeting the tumor microenvironment: How to
convert 'Cold' tumors to 'Hot' tumors. Int J Mol Sci. 25:72082024.
View Article : Google Scholar
|
|
38
|
Fan Y and He S: The characteristics of
tumor microenvironment in triple negative breast cancer. Cancer
Manag Res. 14:1–17. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ding R and Wang Y, Fan J, Tian Z, Wang S,
Qin X, Su W and Wang Y: Identification of immunosuppressive
signature subtypes and prognostic risk signatures in
triple-negative breast cancer. Front Oncol. 13:11084722023.
View Article : Google Scholar :
|
|
40
|
Yang L, Qi Y, Hu J, Tang L, Zhao S and
Shan B: Expression of Th17 cells in breast cancer tissue and its
association with clinical parameters. Cell Biochem Biophys.
62:153–159. 2012. View Article : Google Scholar
|
|
41
|
Bos R and Sherman LA: CD4+ T-cell help in
the tumor milieu is required for recruitment and cytolytic function
of CD8+ T lymphocytes. Cancer Res. 70:8368–8377. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Biswas SK and Mantovani A: Macrophage
plasticity and interaction with lymphocyte subsets: Cancer as a
paradigm. Nat Immunol. 11:889–896. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fu C, Jiang L, Hao S, Liu Z, Ding S, Zhang
W, Yang X and Li S: Activation of the IL-4/STAT6 signaling pathway
promotes lung cancer progression by increasing M2 myeloid cells.
Front Immunol. 10:26382019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nguyen-Pham TN, Yang DH, Nguyen TA, Lim
MS, Hong CY, Kim MH, Lee HJ, Lee YK, Cho D, Bae SY, et al: Optimal
culture conditions for the generation of natural killer
cell-induced dendritic cells for cancer immunotherapy. Cell Mol
Immunol. 9:45–53. 2012. View Article : Google Scholar
|
|
45
|
Zhang L, Gu S, Wang L, Zhao L, Li T, Zhao
X and Zhang L: M2 macrophages promote PD-L1 expression in
triple-negative breast cancer via secreting CXCL1. Pathol Res
Pract. 260:1554582024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lotfinejad P, Kazemi T, Mokhtarzadeh A,
Shanehbandi D, Niaragh FJ, Safaei S, Asadi M and Baradaran B:
PD-1/PD-L1 axis importance and tumor microenvironment immune cells.
Life Sci. 259:1182972020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Niemeijer AN, Sahba S, Smit EF,
Lissenberg-Witte BI, de Langen AJ and Thunnissen E: Association of
tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB
and OS to nivolumab treatment in NSCLC patients pre-treated with
chemotherapy. Br J Cancer. 123:392–402. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li Y, He M, Zhou Y, Yang C, Wei S, Bian X,
Christopher O and Xie L: The prognostic and clinicopathological
roles of PD-L1 expression in colorectal cancer: A systematic review
and meta-analysis. Front Pharmacol. 10:1392019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang HB, Yao H, Li CS, Liang LX, Zhang Y,
Chen YX, Fang JY and Xu J: Rise of PD-L1 expression during
metastasis of colorectal cancer: Implications for immunotherapy. J
Dig Dis. 18:574–581. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L
and Liu X: Application of PD-1 blockade in cancer immunotherapy.
Comput Struct Biotechnol J. 17:661–674. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Mu L, Yu W, Su H, Lin Y, Sui W, Yu X and
Qin C: Relationship between the expressions of PD-L1 and
tumour-associated fibroblasts in gastric cancer. Artif Cells
Nanomed Biotechnol. 47:1036–1042. 2019. View Article : Google Scholar
|
|
52
|
Okudaira K, Hokari R, Tsuzuki Y, Okada Y,
Komoto S, Watanabe C, Kurihara C, Kawaguchi A, Nagao S, Azuma M, et
al: Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a
mouse pancreatic cancer model. Int J Oncol. 35:741–749.
2009.PubMed/NCBI
|
|
53
|
Gambardella C, Clarizia G, Patrone R, Offi
C, Mauriello C, Romano R, Filardo M, Conzo A, Sanguinetti A,
Polistena A, et al: Advanced hemostasis in axillary lymph node
dissection for locally advanced breast cancer: New technology
devices compared in the prevention of seroma formation. BMC Surg.
18:1252019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Parisi S, Gambardella C, Conzo G, Ruggiero
R, Tolone S, Lucido FS, Iovino F, Fisone F, Brusciano L,
Parmeggiani D and Docimo L: Advanced localization technique for
non-palpable breast cancer: Radiofrequency alone VS combined
technique with ultrasound. J Clin Med. 12:50762023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Parisi S, Ruggiero R, Gualtieri G, Volpe
ML, Rinaldi S, Nesta G, Bogdanovich L, Lucido FS, Tolone S,
Parmeggiani D, et al: Combined LOCalizer and intraoperative
ultrasound localization: First experience in localization of
non-palpable breast cancer. In Vivo. 35:1669–1676. 2021. View Article : Google Scholar :
|
